BORIS subfamily 6-specific CTL clone inhibited the sphere-formation of lung cancer cells.
figure
posted on 2017-03-01, 18:34 authored by Ryota Horibe, Yoshihiko Hirohashi, Takuya Asano, Tasuku Mariya, Takeshi Suzuki, Akari Takaya, Hiroshi Saijo, Yosuke Shionoya, Terufumi Kubo, Munehide Nakatsugawa, Takayuki Kanaseki, Tomohide Tsukahara, Kazue Watanabe, Eri Atsuyama, Shingo Toji, Hiroshi Hirano, Tadashi Hasegawa, Hiroki Takahashi, Noriyuki Sato, Toshihiko Torigoe(A) ELISPOT assay of BORIS subfamily 6-specific and non-specific CTL clones. The reactivity for BORIS C34_24(9) peptide were analyzed by ELISPOT assay. HIV peptide and peptide (-) were used as negative controls. (B) Sphere-formation inhibition assay. BORIS C34_24(9) peptide specific CTL clone (3B9) or non-specific CTL clone (5H6) were co-cultured with SBC5 cells in a sphere-forming condition. After 6 days’ culture, the numbers of spheres were counted. Upper panel indicate the numbers of spheres, and data are shown as means ± SD. Lower panel indicates representative images of spheres. Magnification, x 100. Bar scale is 100 μm.
History
Usage metrics
Categories
Keywords
lung cancer stem-like cellsnovel targetRT-PCRlung cancer immunotherapyvariant subfamily 6site variant subfamily 6MHCCSClung cancer stem-like cell immunotherapy Lung cancerBORIS sf 6-positive HLA-A 2-positive lung carcinoma cellsCytotoxic T lymphocytesBORIS sf 6-specific antibodyBORIS sf 6CICCTL clone cellsBORIS sf 6 mRNAtreatment-resistant lung cancer stem-like cells3 HLA-A 2-positive individualssphere-cultured lung cancer stem-like cells
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC